secwatch.observer — SEC 8-K summary
======================================

Issuer:     KORU Medical Systems, Inc. (KRMD)
CIK:        0000704440
Form:       8-K
Filed at:   2023-11-08T23:59:59+00:00
Accession:  0001161697-23-000567
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

KORU Medical Q3 revenue down 9.8% YoY; cuts full-year guidance to $28.0-$28.5M
------------------------------------------------------------------------------

- Q3 net revenue $7.0M (-9.8% YoY); net loss $1.4M ($0.03/share) vs $1.2M loss prior year.
- Full-year 2023 revenue guidance cut to $28.0-$28.5M from $31.0-$32.5M; gross margin reaffirmed 58%-60%.
- FDA cleared FREEDOM60 Infusion System for use with Hizentra 50 mL prefilled syringes; first such clearance.
- Appointed Ken Miller as CCO effective Nov 6; base salary $360K, bonus up to 50%, and 400,000 stock options.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/704440/000116169723000567/0001161697-23-000567-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/704440/000116169723000567/form_8-k.htm
  HTML page:      https://secwatch.observer/filing/0001161697-23-000567

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer